Prepared by:
University of California, San Francisco-Stanford
Paul A. Heidenreich, M.D., M.Sc., Principal Investigator
Kathryn M. McDonald, M.M.
Trevor Hastie, Ph.D.
Bahaa Fadel, M.D.
Vivian Hagan
Byron K. Lee, M.D.
Mark A. Hlatky, M.D.
File Name Description Software Version File Size _________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 97 SR-1 34KB 8 pages Contents: Title Page, Preface, Acknowledgements, Structured Abstract, Contents, List of Figures and Tables _________________________________________________________________________________ 02body.doc Microsoft Word® Document MS Word® 97 SR-1 274KB 40 pages Contents: Summary, Introduction, Methodology, Results, Conclusions and Future Research _________________________________________________________________________________ 03refs.doc Microsoft Word® Document MS Word® 97 SR-1 76KB 14 pages Contents: References, Evidence Tables Abbreviation Key, Bibliography _________________________________________________________________________________ 04etbl01.doc Microsoft Word® Document MS Word® 97 SR-1 40KB 4 pages Contents: Evidence table 1. Study information: Beta-blockers vs. calcium antagonists _________________________________________________________________________________ 05etbl02.doc Microsoft Word® Document MS Word® 97 SR-1 23KB 1 page Contents: Evidence table 2. Study information: Nitrates vs. calcium antagonists _________________________________________________________________________________ 06etbl03.doc Microsoft Word® Document MS Word® 97 SR-1 20KB 1 page Contents: Evidence table 3. Study information: Beta-blockers vs. nitrates _________________________________________________________________________________ 07etbl04.doc Microsoft Word® Document MS Word® 97 SR-1 37KB 4 pages Contents: Evidence table 4. Trial inclusion criteria: Beta-blockers vs. calcium antagonists _________________________________________________________________________________ 08etbl05.doc Microsoft Word® Document MS Word® 97 SR-1 22KB 1 page Contents: Evidence table 5. Trial inclusion criteria: Nitrates vs. calcium antagonists _________________________________________________________________________________ 09etbl06.doc Microsoft Word® Document MS Word® 97 SR-1 20KB 1 page Contents: Evidence table 6. Trial inclusion criteria: Beta-blockers vs. nitrates _________________________________________________________________________________ 10etbl07.doc Microsoft Word® Document MS Word® 97 SR-1 87KB 4 pages Contents: Evidence table 7. Trial exclusion criteria: Beta-blockers vs. calcium antagonists _________________________________________________________________________________ 11etbl08.doc Microsoft Word® Document MS Word® 97 SR-1 30KB 1 page Contents: Evidence table 8. Trial exclusion criteria: Nitrates vs. calcium antagonists _________________________________________________________________________________ 12etbl09.doc Microsoft Word® Document MS Word® 97 SR-1 25KB 4 pages Contents: Evidence table 9. Trial exclusion criteria: Beta-blockers vs. nitrates _________________________________________________________________________________ 13etbl10.doc Microsoft Word® Document MS Word® 97 SR-1 46KB 4 pages Contents: Evidence table 10. Study information: Patient characteristics: Beta- blockers vs. calcium antagonists _________________________________________________________________________________ 14etbl11.doc Microsoft Word® Document MS Word® 97 SR-1 23KB 1 page Contents: Evidence table 11. Patient characteristics: Nitrates vs. calcium antagonists _________________________________________________________________________________ 15etbl12.doc Microsoft Word® Document MS Word® 97 SR-1 21KB 1 page Contents: Evidence table 19. Quality Indicators: Beta-blockers vs. calcium antagonists _________________________________________________________________________________ 16etbl13.doc Microsoft Word® Document MS Word® 97 SR-1 51KB 4 pages Contents: Evidence table 13. Study interventions: Beta-blockers vs. calcium antagonists _________________________________________________________________________________ 17etbl14.doc Microsoft Word® Document MS Word® 97 SR-1 23KB 1 page Contents: Evidence table 14. Study interventions: Nitrates vs. calcium antagonists _________________________________________________________________________________ 18etbl15.doc Microsoft Word® Document MS Word® 97 SR-1 21KB 1 page Contents: Evidence table 15. Study interventions: Beta-blockers vs. nitrates _________________________________________________________________________________ 19etbl16.doc Microsoft Word® Document MS Word® 97 SR-1 40KB 3 pages Contents: Evidence table 16. Crossover trial execution description: Beta- blockers vs. calcium antagonists _________________________________________________________________________________ 20etbl17.doc Microsoft Word® Document MS Word® 97 SR-1 26KB 1 page Contents: Evidence table 17. Crossover trial execution description: Nitrates vs. calcium antagonists _________________________________________________________________________________ 21etbl18.doc Microsoft Word® Document MS Word® 97 SR-1 21KB 1 page Contents: Evidence table 18. Crossover trial execution description: Beta- blockers vs. nitrates _________________________________________________________________________________ 22etbl19.doc Microsoft Word® Document MS Word® 97 SR-1 42KB 4 pages Contents: Evidence table 19. Quality Indicators: Beta-blockers vs. calcium antagonists _________________________________________________________________________________ 23etbl20.doc Microsoft Word® Document MS Word® 97 SR-1 23KB 1 page Contents: Evidence table 20. Quality Indicators: Nitrates vs. calcium antagonists _________________________________________________________________________________ 24etbl21.doc Microsoft Word® Document MS Word® 97 SR-1 22KB 1 page Contents: Evidence table 21. Quality indicators: Beta-blockers vs. nitrates _________________________________________________________________________________ 25etbl22.doc Microsoft Word® Document MS Word® 97 SR-1 75KB 3 pages Contents: Evidence table 22. Outcomes results: Cardiac death or nonfatal MI, beta-blockers vs. calcium antagonists _________________________________________________________________________________ 26etbl23.doc Microsoft Word® Document MS Word® 97 SR-1 55KB 2 pages Contents: Evidence table 23. Outcomes results: Angina episodes, beta-blockers vs. calcium antagonists _________________________________________________________________________________ 27etbl24.doc Microsoft Word® Document MS Word® 97 SR-1 48KB 2 pages Contents: Evidence table 24. Outcomes results: Nitroglycerin use, beta-blockers vs. calcium antagonists _________________________________________________________________________________ 28etbl25.doc Microsoft Word® Document MS Word® 97 SR-1 42KB 2 pages Contents: Evidence table 25. Outcomes results: Exercise time to ischemia, beta- blockers vs. calcium antagonists _________________________________________________________________________________ 29etbl26.doc Microsoft Word® Document MS Word® 97 SR-1 67KB 3 pages Contents: Evidence table 26. Outcomes results: Adverse events, beta-blockers vs. calcium antagonists _________________________________________________________________________________ 30etbl27.doc Microsoft Word® Document MS Word® 97 SR-1 43KB 1 page Contents: Evidence table 27. Outcomes results: Side effects, beta-blockers vs. calcium antagonists _________________________________________________________________________________ 31etbl28.doc Microsoft Word® Document MS Word® 97 SR-1 29KB 1 page Contents: Evidence table 28. Outcomes results: Cardiac death or nonfatal MI, nitrates vs. calcium antagonists _________________________________________________________________________________ 32etbl29.doc Microsoft Word® Document MS Word® 97 SR-1 25KB 1 page Contents: Evidence table 29. Outcomes results: Angina episodes, nitrates vs. calcium antagonists _________________________________________________________________________________ 33etbl30.doc Microsoft Word® Document MS Word® 97 SR-1 25KB 1 page Contents: Evidence table 30. Outcomes results: Nitroglycerin use, nitrates vs. vs. calcium antagonists _________________________________________________________________________________ 34etbl31.doc Microsoft Word® Document MS Word® 97 SR-1 23KB 1 page Contents: Evidence table 31. Outcomes results: Exercise time to ischemia, nitrates vs. calcium antagonists _________________________________________________________________________________ 35etbl32.doc Microsoft Word® Document MS Word® 97 SR-1 28KB 1 page Contents: Evidence table 32. Outcomes results: Adverse events, nitrates vs. calcium antagonists _________________________________________________________________________________ 36etbl33.doc Microsoft Word® Document MS Word® 97 SR-1 25KB 1 page Contents: Evidence table 33. Outcomes results: Side effects, nitrates vs. calcium antagonists _________________________________________________________________________________ 37etbl34.doc Microsoft Word® Document MS Word® 97 SR-1 26KB 1 page Contents: Evidence table 34. Outcomes results: Cardiac death or nonfatal MI, beta-blockers vs. nitrates _________________________________________________________________________________ 38etbl35.doc Microsoft Word® Document MS Word® 97 SR-1 25KB 1 page Contents: Evidence table 35. Outcomes results: Angina episodes, beta-blockers vs. nitrates _________________________________________________________________________________ 39etbl36.doc Microsoft Word® Document MS Word® 97 SR-1 23KB 1 page Contents: Evidence table 36. Outcomes results: Angina episodes, beta-blockers vs. nitrates _________________________________________________________________________________ 40etbl37.doc Microsoft Word® Document MS Word® 97 SR-1 21KB 1 page Contents: Evidence table 37. Outcomes results: Exercise time to ischemia, beta-blockers vs. nitrates _________________________________________________________________________________ 41etbl38.doc Microsoft Word® Document MS Word® 97 SR-1 25KB 1 page Contents: Evidence table 38. Outcomes results: Adverse events, beta-blockers vs. nitrates _________________________________________________________________________________ 42etbl39.doc Microsoft Word® Document MS Word® 97 SR-1 23KB 1 page Contents: Evidence table 39. Outcomes results: Side effects, beta-blockers vs. nitrates _________________________________________________________________________________
AHRQ Publication No. 00-E003
Current as of November 1999
Internet Citation:
An Evaluation of Beta-Blockers, Calcium Antagonists, Nitrates, and Alternative Therapies for Stable Angina. File Inventory, Evidence Report/Technology Assessment Number 10. AHRQ Publication No. 00-E003, November 1999. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/stableinv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services